Weekly issue 2026-W38 ·
Association Between Tolvaptan Exposure and Venous Thromboembolism Risk in ADPKD: A Real-World Propensity-Matched EHR Study
Plain language
Blood clots in the veins seem a little more common in people with ADPKD. Using health records from about 39,000 adults, researchers compared people who took tolvaptan with closely matched people who did not. Those on tolvaptan had fewer clots (about 2 in 100 vs 4 in 100) and fewer deaths. But this kind of study cannot prove the medicine caused the difference — people prescribed tolvaptan may simply differ in other ways.
Clinical note
Retrospective TriNetX cohort, adults with ADPKD (Q61.2) 2000–2025, inherited thrombophilia excluded; 1:1 PSM on 24 covariates (1,333 pairs). Tolvaptan associated with lower VTE (2.1% vs 3.9%; RR 0.54, 95% CI 0.34–0.85), all-cause mortality (1.28% vs 3.9%; RR 0.33) and antithrombotic use (RR 0.69). Exposure fixed at entry; no imaging-based severity (TKV/Mayo class), so residual confounding and healthy-user bias are likely. Reassuring on thrombotic safety; hypothesis-generating, not causal.
Question for your next visit
Does ADPKD change my risk of blood clots, and is there anything about my treatment or daily habits that matters for that risk?